Sugi Predict

Sugi Predict / Compounds / SCHEMBL5033246

SCHEMBL5033246

SCHEMBL5033246

CC(C)(C)OC(=O)N[C@H](CCCO)C(=O)OC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 10/20 0.51
▸ CTSS P25774 5/20 0.49
▸ TDP1 Q9NUW8 3/20 0.47
▸ ATM Q13315 1/20 0.44
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ P2RY2 P41231 1/20 0.43
▸ HDAC4 P56524 2/20 0.43
▸ HDAC1 Q13547 2/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19695765 1.00 CTSK (0.51) CTSKCTSSTDP1ATMCYP1A2
SCHEMBL613038 1.00 CTSK (0.51) CTSKCTSSTDP1ATMCYP1A2
SCHEMBL613037 1.00 CTSK (0.51) CTSKCTSSTDP1ATMCYP1A2
SCHEMBL14682815 0.95 CTSK (0.50) CTSKCTSSTDP1ATMCYP1A2
SCHEMBL31591658 0.95 CTSK (0.50) CTSKCTSSTDP1ATMCYP1A2
SCHEMBL3732677 0.92 CTSK (0.50) CTSKCTSSTDP1CYP1A2CYP2C9
SCHEMBL3969261 0.92 CTSK (0.50) CTSKCTSSTDP1CYP1A2CYP2C9
SCHEMBL29727300 0.92 CTSK (0.50) CTSKCTSSTDP1CYP1A2CYP2C9
SCHEMBL24214307 0.90 CTSK (0.47) CTSKCTSSTDP1CYP1A2CYP2C9
SCHEMBL6296123 0.90 CTSK (0.47) CTSKCTSSTDP1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371434-B2 MLL1 inhibitors and anti-cancer agents CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2025-07-29 — — US disclosed
CN-114929705-B MLL1 inhibitors and anticancer agents 诺华公司 2024-09-13 — — CN disclosed
EP-4013754-B1 MLL1 INHIBITORS AND ANTI-CANCER AGENTS NOVARTIS AG (CH) 2024-07-24 — — EP disclosed
US-20240059734-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2024-02-22 — — US disclosed
US-11795196-B2 Mitochondria-targeting peptides STEALTH BIOTHERAPEUTICS INC. (US) 2023-10-24 — — US disclosed
US-11795196-B2 Mitochondria-targeting peptides STEALTH BIOTHERAPEUTICS INC. (US) 2023-10-24 — — US disclosed
EP-4218785-A2 MITOCHONDRIA-TARGETING PEPTIDES Stealth BioTherapeutics Inc. (US) 2023-08-02 — — EP disclosed
EP-4218785-A2 MITOCHONDRIA-TARGETING PEPTIDES Stealth BioTherapeutics Inc. (US) 2023-08-02 — — EP disclosed
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2023-05-11 — — US disclosed
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC. 2023-05-11 — — US disclosed
CN-114929705-A MLL1 inhibitor and anticancer agent 诺华公司 2022-08-19 — — CN disclosed
EP-4013754-A1 MLL1 INHIBITORS AND ANTI-CANCER AGENTS Novartis AG (CH) 2022-06-22 — — EP disclosed
WO-2019118878-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS CORP. (MC) 2019-06-20 — — WO disclosed
US-9840457-B2 Lysine isotopologues, compositions comprising the same and methods of synthesis CAMBRIDGE ISOTOPE LABORATORIES, INC. (US) 2017-12-12 — — US disclosed
US-9840457-B2 Lysine isotopologues, compositions comprising the same and methods of synthesis CAMBRIDGE ISOTOPE LABORATORIES, INC. (US) 2017-12-12 — — US disclosed
US-20160016890-A1 LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS CAMBRIDGE ISOTOPE LABORATORIES, INC. 2016-01-21 — — US disclosed
US-20160016890-A1 LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS CAMBRIDGE ISOTOPE LABORATORIES, INC. 2016-01-21 — — US disclosed
EP-1918278-A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases Novartis AG (CH) 2008-05-07 — — EP disclosed
US-6410580-B1 ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES NOVARTIS AG (CH) 2002-06-25 — — US disclosed
US-6277987-B1 FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS NOVARTIS AG (CH) 2001-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12371434-B2 MLL1 inhibitors and anti-cancer agents MLLT1, BMI1, DOT1L CTSK 4303/4885CTSS 4653/4885TDP1 1975/4885
US-20160016890-A1 LYSINE ISOTOPOLOGUES, COMPOSITIONS COMPRISING THE SAME AND METHODS OF SYNTHESIS PLOD1, PHYKPL, AADAT CTSK 785/4885CTSS 2046/4885TDP1 1130/4885
US-11795196-B2 Mitochondria-targeting peptides HSPE1, TFAM, TNNI3 CTSK 909/4885CTSS 1818/4885TDP1 2124/4885
US-20240059734-A1 MITOCHONDRIA-TARGETING PEPTIDES HSPE1, TFAM, TNNI3 CTSK 909/4885CTSS 1818/4885TDP1 2124/4885
US-20230146515-A1 MITOCHONDRIA-TARGETING PEPTIDES HSPE1, TFAM, TNNI3 CTSK 909/4885CTSS 1818/4885TDP1 2124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.